Skip to content

Breaking Down Barriers to Diabetes Self-Care

Breaking Down Barriers to Diabetes Self-Care

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00142922
Enrollment
222
Registered
2005-09-02
Start date
2002-10-31
Completion date
2007-10-31
Last updated
2010-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes, Type 2 Diabetes

Keywords

Adherence, self-care, Behavioral intervention, Diabetes

Brief summary

Performance of self-care recommendations is key to the successful treatment of diabetes. However, many patients have difficulty adhering to diabetes self-care recommendations. Recent results from our own studies and others have identified specific barriers to diabetes self-care. To evaluate the efficacy of a diabetes educator-led group intervention, the Breaking Down Barriers Program, that addresses barriers and therefore leads to improved adherence to diabetes self-care recommendations, we will randomize 222 (111 type 1 and 111 type 2) diabetes patients to one of three conditions: 1) the Breaking Down Barriers Program, 2) a cholesterol attention control condition, or 3) a 'usual care' control condition. We hypothesize that those assigned to the Breaking Down Barriers group will improve self-care behaviors and glycemic control more than those in the two control groups. We will follow study subjects for one year to determine whether their self-care behaviors and glycemic control improved and if the improvement was maintained over time.

Interventions

BEHAVIORALBreaking Down Barriers

completed

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

For Patients With Type 1 Diabetes * Aged 18-65 * Presence of type 1 diabetes mellitus. * 2-25 year duration. For Patients With Type 2 Diabetes * Aged 25-65 years * presence of type 2 diabetes mellitus. * 2 years since initial diagnosis.

Exclusion criteria

* Renal disease, microalbumin \>300 ug/mg) * Severe peripheral diabetic neuropathy and/or severe peripheral vascular disease * Symptomatic severe autonomic neuropathy who may be at risk when increasing activity levels. * Women who are currently pregnant * proliferative diabetic retinopathy based on dilated eye examination within one year of study entry. Patients whose eye disease is successfully treated will be included. * HbA1c levels less than 7.0% (normal range 4.0 - 6.0%). * HbA1c levels greater than 14.0% * patients who underwent intensive insulin treatment within one year * a history of severe, unstable myocardial infarction, congestive heart failure or other severe cardiac disease, severe hypertension (systolic more than 160 mmHg or diastolic 90 mmHg) who may be at risk when mildly increasing physical activity * a DSMIV diagnosis of eating disorders including anorexia nervosa, bulimia, and severe weight-related insulin omission. * Patients with recent diagnosis (past 6 months) of bipolar disorder, schizophrenia, mental retardation, organic mental disorder, and alcohol or drug abuse * Patients whose diabetes diagnosed cannot be clearly classified as type 1 or type 2.

Design outcomes

Primary

MeasureTime frame
Self-Care Behaviors
Glycemic control (HbA1c)
fitness

Secondary

MeasureTime frame
Quality of life
Diabetes Related emaitonal distress

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026